Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) is now available.
Hemogenyx Pharmaceuticals has confirmed that the UK Financial Conduct Authority has scheduled an admission hearing for its new ordinary shares on 5 January 2026, with trading in the new shares expected to commence at around 8:00 a.m. on 6 January 2026. The timing update indicates the capital-related process is progressing as planned, with all other terms from the company’s 18 December 2025 announcement remaining unchanged, providing investors and other stakeholders with clarity on the anticipated schedule for the shares’ admission to trading.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals plc is a London-headquartered, clinical-stage biopharmaceutical company listed on the London Stock Exchange (LSE: HEMO), with operating subsidiaries in New York City. The group focuses on developing new medicines and treatments for blood and autoimmune diseases, supported by a portfolio of distinct but complementary product candidates and proprietary platform technologies that serve as engines for novel drug development.
Average Trading Volume: 51,825
Technical Sentiment Signal: Hold
Current Market Cap: £35.39M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.